Phenobarbital, also known as Luminal, is a prescription medication used to treat epilepsy and also as a secondary medication for anxiety and insomnia. It works by slowing down impulses in the brain that cause seizures. Phenobarbital comes in tablet, capsule, and injectable forms. The drug is very cost effective and its generic version is easily available, making it popular worldwide for treatment of epilepsy and seizures. However, its prolonged use may cause side effects such as sleepiness, irritability, or hyperactivity in some cases.
The Global Phenobarbital Market is estimated to be valued at US$ 1.83 Bn in 2024 and is expected to exhibit a CAGR of 7.2% over the forecast period 2024 to 2031.
Key Takeaways
Key players operating in the Phenobarbital market are Yara International ASA, BASF SE, The Mosaic Company, FMC Corporation, Nouryon Cooperatief UA, Nutrien Limited, Haifa Group, Valagro SpA (Syngenta Group), Coromandel International Limited, Sapec Agro SA, Auriga Group, ATP Nutrition Ltd, Wilbur-Ellis Company LLC, BMS Micro-Nutrients NV, and UPL Limited (Arysta Lifescience Corporation).
The growing prevalence of epilepsy worldwide is a major factor fueling the demand for anti-seizure medications such as phenobarbital. According to the World Health Organization, around 50 million people suffer from epilepsy globally. Increasing healthcare expenditure and awareness about epilepsy treatment is further boosting the phenobarbital market.
The market is witnessing expansion in developing regions due to rising disposable income, healthcare spending, and government initiatives to spread epilepsy awareness in these countries. Key players are focusing on strengthening their distribution network in Asia Pacific and Latin American countries to tap the growth opportunities.
Market drivers
The increasing prevalence of epilepsy is a key driver for the Phenobarbital Market Demand. As per the WHO, the lifetime prevalence of epilepsy is estimated to range from 4 to 10 cases per 1000 population across different regions. Around 50 million people worldwide have epilepsy currently. Additionally, head injuries, brain infections, brain tumors and genetic factors also contribute to epilepsy incidence. Phenobarbital remains the first line therapy for controlling seizures in newly diagnosed patients and is preferred due to its low cost and effectiveness. This growing disease prevalence worldwide will continue to drive the demand for anti-seizure drugs like phenobarbital.
Geopolitical Impact on Phenobarbital Market Growth
The current geopolitical tensions and uncertainties brought on by the Russia-Ukraine conflict is negatively impacting the phenobarbital market. Both Ukraine and Russia are among the leading exporters and producers of fertilizers globally. The war has disrupted exports from the Black Sea region which is a major hub for fertilizer shipments. This has led to supply chain disruptions and shortage of key fertilizer inputs like ammonia and urea used for phenobarbital production. Rising energy costs due to sanctions on Russia is also increasing production costs for phenobarbital manufacturers. Many companies have reduced or halted fertilizer exports to prioritize domestic agricultural needs over exports, worsening the global supply issues. The ongoing trade sanctions and export restrictions are expected to continue hindering the phenobarbital market growth over the short to medium term until the geopolitical issues are resolved.
European Region Dominates Phenobarbital Market Value
Europe currently dominates the phenobarbital market in terms of value and is estimated to account for over 30% share of the global market revenue. Significant demand comes from countries like Germany, France, UK, Italy and Spain where phenobarbital is widely used as an anticonvulsant and sedative in pharmaceutical applications. Europe is a leader in cutting-edge biopharmaceutical research which is driving innovations and new product developments involving phenobarbital. Strong distribution networks of major players along with stringent regulations have helped establish Europe as the highest valued region. With increasing collaborations between research institutes and manufacturers, Europe is anticipated to retain its leading position over the forecast period.
Asia Pacific Emerges as Fastest Growing Region
The Asia Pacific region has emerged as the fastest growing market for phenobarbital globally and is estimated to expand at a CAGR of around 8.5% till 2031. Rapid growth in the pharmaceutical, agrochemical and animal feed industries across developing nations such as India, China, Indonesia and Vietnam is creating high demand for phenobarbital. The increasing meat consumption and rising awareness about livestock health in Asia is boosting phenobarbital adoption in animal feed applications. In addition, growing population, rising disposable incomes and expansion of healthcare infrastructure across Asia Pacific economies is anticipated to drive above average growth in the medical and agrochemical segments, making it the most lucrative regional market.
Get more insights on Phenobarbital Market
Also read related article on m-RNA Synthesis Service Market
